Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heterologous rDEN1Δ30 and rDEN2Δ30-7169 Dengue Vaccine Challenge
NCT02392325Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2015
- Primary completion
- Jul 2016
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in dengue fever comparing rDEN1Δ30 and rDEN2Δ30-7169 with Placebo and rDEN2Δ30-7169 (2 arms). Primary endpoints: Plaque Reduction Neutralization Titer 50 at Day 90, Incidence of Solicited Adverse Events at Day 450 and 1 more. Started Mar 2015; status: completed.
02
Drugs
rDEN1Δ30rDEN2Δ30-7169
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT02392325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02392325.